AWV Practice Redesign Toolkit (Tailored Intervention)

Status Enrolling by invitation

Clinical Trial Summary

The goal of this study is to improve the use of preventive health services by implementing the AWV Practice Redesign Toolkit to stimulate AWV visit use in diverse practices across the United States. This is a stepped wedge cluster randomized controlled trial. The intervention will be implemented in a total of 16 small-to-mid-size primary care practices (at the practice level) with clinicians and staff. Eight practices will participate in the main clinical trial, and 8 in a replication study. The main clinical trial (with community-based practices) and replication study (with Federally Qualified Health Center practices) will be conducted simultaneously. Electronic health record (EHR) data extractions will be used to collect outcomes in a population cohort of patients. Semi-structured interviews will be conducted with clinicians/staff and patients to assess intervention implementation. The investigators hypothesize that the toolkit implementation will increase AWV visit use and consequently, use of preventive health services.

Clinical Trial Description

This is a multi-site, stepped wedge cluster randomized controlled trial to evaluate the effect of the AWV Practice Redesign Toolkit on AWV and preventive health services use. The study will take place in 16 primary care practices around the United States. Eight practices will participate in the main clinical trial, and 8 in a replication study. The main clinical trial (with community-based practices) and replication study (with Federally Qualified Health Center practices) will be conducted simultaneously. Recruitment occurs at the level of the practice. The investigators hypothesize that the intervention will increase uptake of AWVs and use of preventive health services. The stepped wedge cluster design is a pragmatic study design that includes an initial control period in which no clusters receive the intervention. Randomized clusters cross to the intervention condition at regular intervals, and there is a period at the end of the study where all clusters have been exposed to the intervention. Data are collected throughout the study so that each cluster contributes to both the control and intervention periods. The intervention will be implemented sequentially over 16 months, with 4 clusters of 4 practices each switching from control to intervention every 4 months between months 4-20. By month 20 of the study all practices will have completed intervention implementation. Each cluster will have a 4 month transition period during intervention implementation. In addition to the procedures described above, the investigators will collect qualitative semi-structured interview data on a subset of patients (up to n=10), and clinicians/staff (up to n=10) from each practice to assess fidelity to the intervention. Outcomes will be assessed through EHR data extractions, which will be led by the DARTNet Institute (co-investigator Wilson Pace). Data will be sent from the DARTNet Institute to the American Academy of Family Physicians National Research Network (AAFP NRN) for cleaning, de-identification and creation of flags. The AAFP NRN has established contracts and agreements with the DARTNet Institute that enables them to access DARTNet's data. The AAFP NRN will deliver a limited dataset to investigators at the University of California, Los Angeles for analyses. ;

Study Design

Related Conditions & MeSH terms

Preventive Health Services

Clinical Trial Details

NCT number	NCT05563415
Study type	Interventional
Source	University of California, Los Angeles
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	May 15, 2023
Completion date	August 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05336240` - PCOM2 - The Physician Communication Intervention, Version 2.0	N/A
Recruiting	`NCT01120041` - Community-based Intergenerational Oral Health Study	Phase 3
Not yet recruiting	`NCT05910736` - Increasing the Feasibility, Impact, and Equity of the Medicare Annual Wellness Visit (AWV)	N/A
Completed	`NCT03797898` - Well-Child Care Clinical Practice Redesign: A Parent Coach-Led Model of Care	N/A
Active, not recruiting	`NCT03583840` - Effectiveness of a Web-based Intervention to Promote Health Screening in Men	N/A
Completed	`NCT02708745` - Screening for Hesitancy to Optimize Talk	N/A
Not yet recruiting	`NCT06312410` - The VIA Family 2.0 - a Family Based Intervention for Families With Parental Mental Illness	N/A
Completed	`NCT02262962` - Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families	N/A
Completed	`NCT00327457` - Coordinated Endoscopic Colorectal Cancer Screening	N/A
Completed	`NCT03550066` - Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention	N/A
Completed	`NCT00793260` - Deep Dive Randomized Control Trial	N/A
Completed	`NCT05702008` - Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional Study	N/A
Completed	`NCT02993965` - State Immunization Information Systems to Improve HPV Vaccination Rates	N/A
Enrolling by invitation	`NCT04743050` - The ALA, DHA and EPA Esters in the Prevention of Cardiovascular Diseases.	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.